Danish drugmaker LEO Pharma said on Thursday it had agreed to buy U.S. drug developer Replay for $50 million upfront, adding an experimental treatment platform for rare genetic skin diseases to its dermatology business.
April 30 (Reuters) – Danish drugmaker LEO Pharma said on Thursday it had agreed to buy U.S. drug developer Replay for $50 million upfront, adding an experimental treatment platform for rare genetic skin diseases to its dermatology business.
The dea… [1511 chars]
Source: Reuters | Published: 2026-04-30T13:05:59Z
Credit: Reuters
